Advertisement

Role of Endocrine-Genotoxic Switchings in Cancer and Other Human Diseases:

Basic Triad
  • Lev M. Berstein
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 630)

Abstract

Cancer is one of the leading causes of human death and belongs to the group of main chronic noncommunicable diseases (NCD). Certain specific features of NCD have raised the concept of ‘normal’ and ‘successful’ aging. The apparent paradox of simultaneous increase with aging of the diseases connected with estrogen deficiency as well as with estrogenic excess can be explained by the existence of the phenomenon of the switching of estrogen effects. An isolated or combined with the weakening of hormonal effect increase in genotoxic action of estrogens can modify the course of age-associated pathology. In particular, such changes in estrogen effect may alter the biology of tumors to make them less favorable/more aggressive. Two other endocrine-genotoxic switchings (EGS) involving phenomena of Janus (dual) function of glucose and adipogenotoxicosis may produce similar influences on tumor and other NCD biology. These three phenomena form a ‘basic triad’ and can act independently of each other or in concert. EGS and their inductors may serve as targets for prevention and, probably, treatment of main noncommunicable diseases. The measures to correct components of the ‘triad’ can be divided into several groups aimed to optimally orchestrate the balance between endocrine and DNA-damaging effects of estrogens, glucose and adipose tissue-related factors.

Keywords

Breast Cancer Adipose Tissue Glycemic Load Noncommunicable Disease Estradiol Valerate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Intern Med 2000; 247(3):301–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Unwin N, Alberti KG. Chronic noncommunicable diseases. Ann Trop Med Parasitol 2006; 100(5–6):455–64.PubMedCrossRefGoogle Scholar
  3. 3.
    Baltes PB, Baltes MM. Psychological perspectives on successful aging: The model of selective optimization with compensation. In: Baltes PB, Baltes MM., eds. Successful aging: perspectives from the behavioral sciences. Cambridge, England: Cambridge University Press, 1990:1–34.Google Scholar
  4. 4.
    Rowe JW, Kahn RL. Human aging: usual and successful. Science 1987; 237(4811):143–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Kahn RL. Guest editorial. On “Successful ageing and well-being: self-rated and compared with Rowe and Kahn”. The Gerontologist 2002; 42:725–726.PubMedGoogle Scholar
  6. 6.
    Liehr JG. Dual role of oestrogens as hormones and procarcinogens: tumour initiation by metabolic activation of oestrogens. Eur J Cancer Prevention 1997; 6:3–10.CrossRefGoogle Scholar
  7. 7.
    Cavalieri EL, Li KM, Balu N et al. Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 2002; 23:1071–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Santen RJ. Endocrine-responsive cancer. In: Larsen PR. et al. eds. Williams’ Textbook of Endocrinology. Philadelphia: W.B. Saunders Comp, 2003:1797–833.Google Scholar
  9. 9.
    Berstein LM. Modern concepts of hormonal carcinogenesis: mechanisms, predisposing factors, consequences. In: Berstein LM, ed. Hormones, age and cancer. St. Peterburg: Nauka, 2005:38–67.Google Scholar
  10. 10.
    Berstein LM, Tsyrlina EV, Vasilyev DA et al. Phenomenon of the switching of estrogen effects and joker function of glucose: similarities, relation to age-associated pathology, approaches to correction. Annals NY Acad Sci 2005; 1057:235–246.CrossRefGoogle Scholar
  11. 11.
    Berstein LM, Vasilyev DA, Poroshina TE et al. Glucose-induced effects and joker function of glucose: endocrine or genotoxic prevalence? Hormone Metabol Research 2006; 38:650–5.CrossRefGoogle Scholar
  12. 12.
    Berstein LM, Kovalevskij AY, Poroshina TE et al. Signs of proinflammatory/genotoxic switch (adipogenotoxicosis) in mammary fat of breast cancer patients: role of menopausal status, estrogens and hyperglycemia. International J Cancer 2007; 121:514–9.CrossRefGoogle Scholar
  13. 13.
    Ehebauer M, Hayward P, Martinez Arias A. Notch, a universal arbiter of cell fate decisions. Science 2006; 314(5804):1414–5.PubMedCrossRefGoogle Scholar
  14. 14.
    Flexner S, Flexner D. Wise words: the origins, meanings and time-honored wisdom of proverbs. New York: Avon Books 1993.Google Scholar
  15. 15.
    Burrows H, Horning E. Oestrogens and neoplasia. Springfield, Illinois: Ch C Thomas Publ, 1952.Google Scholar
  16. 16.
    Henderson B, Feigelson H. Hormonal carcinogenesis. Carcinogenesis 2000; 21:427–33.PubMedCrossRefGoogle Scholar
  17. 17.
    Li JJ, Li SA, Oberley TD et al. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation. Cancer Res 1995; 55:4347–51.PubMedGoogle Scholar
  18. 18.
    Yue W, Santen RJ, Wang JP et al. Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 2003; 86(3–5):477–86.PubMedCrossRefGoogle Scholar
  19. 19.
    Suto A, Telang NT, Tanino H et al. In vitro and in vivo modulation of growth regulation in the human breast cancer cell line MCF-7 by estradiol metabolites. Breast Cancer 1999; 6:87–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Jefcoate CR, Liehr JG, Santen RJ et al. Tissue-specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monograph 2000; 27:95–112.Google Scholar
  21. 21.
    Cavalieri EL, Chakravarti D, Guttenplan J et al. Catechol estrogen quinones as initiators of breast and other human cancers: Implications for biomarkers of susceptibility and cancer prevention. Biochim Biophys Acta 2006; 1766:63–78.PubMedGoogle Scholar
  22. 22.
    Tsuchiya Y, Nakajima M, Kyo S. et al. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res 2004; 64:3119–25.PubMedCrossRefGoogle Scholar
  23. 23.
    Berstein LM. Hormonal carcinogenesis. St. Petersburg: Nauka Publ, 2000.Google Scholar
  24. 24.
    Berstein L, Tsyrlina E, Poroshina T et al. Switching (overtargeting) of estrogen effects and its potential role in hormonal carcinogenesis. Neoplasma 2002; 49:21–25.PubMedGoogle Scholar
  25. 25.
    Michnovicz JJ, Herschcopf RJ, Nagamura H. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. New Engl J Med 1986; 315:1305–09.PubMedGoogle Scholar
  26. 26.
    Port JL, Yamaguchi K, Du B et al. Tobacco smoke induces CYP1B1 in the aerodigestive tract. Carcinogenesis 2004; 25:2275–81.PubMedCrossRefGoogle Scholar
  27. 27.
    Berstein LM, Yue W, Wang JP et al. Estrogenic effects and their modification by tobacco smoke in wild type and estrogen deprived breast cancer cell lines. Paper presented at: The Endocrine Society’s (USA) 89th Annual Meeting. Canada: Toronto, 2007.Google Scholar
  28. 28.
    King MM, Hollingsworth A, Cuzick J et al. The detection of adducts in human cervix tissue DNA using 32P-postlabelling: a study of the relationship with smoking history and oral contraceptive use. Carcinogenesis 1994; 15:1097–100.PubMedCrossRefGoogle Scholar
  29. 29.
    Berstein LM, Tsyrlina EV, Kolesnik OS et al. Catecholestrogens excretion in smoking and nonsmoking postmenopausal women receiving estrogen replacement therapy. J Steroid Biochem Mol Biol 2000; 72:143–7.PubMedCrossRefGoogle Scholar
  30. 30.
    Tarone RE, Chu KC. The greater impact of menopause on ER− than ER+ breast cancer incidence: a possible explanation. Cancer Causes and Control 2002; 13:7–14.PubMedCrossRefGoogle Scholar
  31. 31.
    Althuis MD, Fergenbaum JH, Garcia-Closas M et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev 2004; 13:1558–68.PubMedGoogle Scholar
  32. 32.
    Anderson WF, Matsuno R. Breast cancer heterogeneity: a mixture of at least two main types? J Natl Cancer Inst 2006; 98:948–51.PubMedCrossRefGoogle Scholar
  33. 33.
    Fan S, Ma YX, Wang C et al. Role of direct interaction in BRCA1 inhibition of estrogen receptor activity. Oncogene 2001; 20:77–87.PubMedCrossRefGoogle Scholar
  34. 34.
    Sorlie T, Tibshirani R, Parker J et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003; 100:8418–23.PubMedCrossRefGoogle Scholar
  35. 35.
    Fazzari A, Catalano MG, Comba A et al. The control of estrogen and progesterone receptor expression in MCF-7 breast cancer cells: effects of estradiol and sex hormone binding globulin. Mol Cell Endocrinol 2001; 172:31–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Berstein LM, Tsyrlina EV, Poroshina TE et al. Genotoxic factors associated with the development of receptor-negative breast cancer: potential role of the phenomenon of switching of estrogen effects. Experimental Oncology 2006; 28(1):64–9.PubMedGoogle Scholar
  37. 37.
    Fuqua SAW. Estrogen and progesterone receptors and breast cancer. In: Harris JR et al, eds. Diseases of breast. Philadelphia: Lippincott-Raven 1996; 185–200.Google Scholar
  38. 38.
    Osborne CK, Schiff R, Arpino G et al. Endocrine responsiveness: understanding how progesterone receptor can be used to select endocrine therapy. Breast 2005; 14(6):458–65.PubMedCrossRefGoogle Scholar
  39. 39.
    Abd El-Rehim DM, Pinder SE, Paish CE et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004; 203:661–71.PubMedCrossRefGoogle Scholar
  40. 40.
    Fentiman IS, Allen DS, Hamed D. Smoking and prognosis in women with breast cancer. Int J Clin Pract 2005; 59(9):1051–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Manjer J, Malina J, Berglund G et al. Smoking associated with hormone receptor negative breast cancer. Int J Cancer 2001; 91(4):580–4.PubMedCrossRefGoogle Scholar
  42. 42.
    Sartorius CA, Harvell DM, Shen T et al. Progestins initiate a luminal to myoepithelial switch in estrogen-dependent human breast tumors without altering growth. Cancer Res 2005; 65:9779–88.PubMedCrossRefGoogle Scholar
  43. 43.
    Sherwin BB. Estrogen and cognitive functioning in women. Endocr Rev 2003; 24:133–51.PubMedCrossRefGoogle Scholar
  44. 44.
    Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006; 24:4783–91.PubMedCrossRefGoogle Scholar
  45. 45.
    Schwartz D, Rotter V. p53-dependent cell cycle control: response to genotoxic stress. Semin Cancer Biol 1998; 8(5):325–36.PubMedCrossRefGoogle Scholar
  46. 46.
    Safe S, Wormke M, Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J Mammary Gland Biol Neoplasia 2000; 5:295–306.PubMedCrossRefGoogle Scholar
  47. 47.
    Tritscher AM, Seacat AM, Yager JD et al. Increased oxidative DNA damage in livers of TCDD treated intact but not ovariectomized rats. Cancer Letters 1996; 98:219–25.PubMedGoogle Scholar
  48. 48.
    Chen ZH, Hurh YJ, Na HK et al. Resveratrol inhibits TCDD-induced expression of CYP1A1 and CYP1B1 and catechol estrogen-mediated oxidative DNA damage in cultured human mammary epithelial cells. Carcinogenesis 2004; 25:2005–13.PubMedCrossRefGoogle Scholar
  49. 49.
    Dilman VM. Development, ageing and disease. A new rationale for an intervention strategy. Chur (Switzerland): Harwood Acad Publ 1994.Google Scholar
  50. 50.
    Reaven GM. The insulin resistance syndrome. Curr Atheroscler Rep 2003; 5:364–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Fernandez-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocrine Rev 2003; 24:278–301.CrossRefGoogle Scholar
  52. 52.
    Brand-Miller JC. Glycemic load and chronic disease. Nutr Rev 2003; 61(5 Pt 2):S49–S55.PubMedCrossRefGoogle Scholar
  53. 53.
    Silvera SA, Jain M, Howe GR et al. Dietary carbohydrates and breast cancer risk: A prospective study of the roles of overall glycemic index and glycemic load. Int J Cancer 2005;114:653–8.PubMedCrossRefGoogle Scholar
  54. 54.
    Kwon G, Marshall CA, Liu H et al. Glucose-stimulated DNA synthesis through mammalian target of rapamycin (mTOR) is regulated by KATP channels: effects on cell cycle progression in rodent islets. J Biol Chem 2006; 281(6):3261–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Blagosklonny MV. Aging and immortality. Quasi-programmed senescence and its pharmacological inhibition. Cell Cycle 2006; 18:2087–102.Google Scholar
  56. 56.
    Saydah SH, Loria CM, Eberhardt MS et al. Abnormal glucose tolerance and the risk of cancer death in the United States. Amer J Epidemiol 2003; 157:1092–100.CrossRefGoogle Scholar
  57. 57.
    Bershtein LM. (The joker function of glucose in the development of main noncommunicable human diseases). Vestn. Russian Acad Med Sci 2005; N2:48–51.Google Scholar
  58. 58.
    Ferrannini E, Gastaldelli A, Miyazaki Y et al. β-cell function in subjects spanning the range from normal glucose tolerance to overt diabetes: a new analysis. J Clin Endocr Metabol 2005; 90:493–500.CrossRefGoogle Scholar
  59. 59.
    Rossetti L, Giacarri A, DeFronzo RA. Glucose toxicity. Diabetes Care 1990; 13:610–30.PubMedCrossRefGoogle Scholar
  60. 60.
    Dandona P, Thusu K, Cook S et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996; 347:444–5.PubMedCrossRefGoogle Scholar
  61. 61.
    Ceriello A, Quatraro A, Giugliano D. Diabetes mellitus and hypertension: the possible role of hyperglycaemia through oxidative stress. Diabetologia 1993;36:265–6.PubMedCrossRefGoogle Scholar
  62. 62.
    Lin Y, Berg AH, Iyengar P et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005; 280:4617–26.PubMedCrossRefGoogle Scholar
  63. 63.
    Mohanty P, Hamouda W, Garg R et al. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metabol 2000; 85:2970–3.CrossRefGoogle Scholar
  64. 64.
    Vlassara H, Cai W, Crandall J et al. Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 2002; 99:15596–601.PubMedCrossRefGoogle Scholar
  65. 65.
    Choi SW, Benzie IF, Lam CS et al. Inter-relationship between DNA damage, ascorbic acid and glycaemic control in type 2 diabetes mellitus. Diabetic Med 2005; 22:1347–53.PubMedCrossRefGoogle Scholar
  66. 66.
    Andreassi MG, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med 2003; 13:270–5.PubMedCrossRefGoogle Scholar
  67. 67.
    Dandona P, Aljada A, Mohanty P et al. Insulin inhibits intranuclear factor kB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect. J Clin Endocrinol Metabol 2001; 86:3257–65.CrossRefGoogle Scholar
  68. 68.
    Vasilyev DA, Poroshina TE, Kovalenko IG et al. [Carbohydrates-induced endocrine and genotoxic effects as a potential cancer risk factor]. Presented at 2nd Russian Conference on fundamental oncology. St Petersburg 2006.Google Scholar
  69. 69.
    Houston TK, Person SD, Pletcher MJ et al. Active and passive smoking and development of glucose intolerance among young adults in a prospective cohort: CARDIA study. BMJ 2006; 332(7549):1064–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Smith SR, Wilson PWF. Editorial: free fatty acids and atherosclerosis—guilty or innocent? J Clin Endocrinol Metabol 2006; 91(7):2506–8.CrossRefGoogle Scholar
  71. 71.
    Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004; 4:579–91.PubMedCrossRefGoogle Scholar
  72. 72.
    Berstein LM. Macrosomy, obesity and cancer. New York: Nova Sci Publ 1997.Google Scholar
  73. 73.
    Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metabol 2004; 89:2548–56.CrossRefGoogle Scholar
  74. 74.
    Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. Diabetes 2006; 55:1537–45.PubMedCrossRefGoogle Scholar
  75. 75.
    Lorincz AM, Sukumar S. Molecular links between obesity and breast cancer. Endocr Relat Cancer 2006; 13:279–92.PubMedCrossRefGoogle Scholar
  76. 76.
    Catalano S, Marsico S, Giordano C et al. Leptin enhances, via AP-1, expression of aromatase in the MCF-7 cell line. J Biol Chem 2003; 278:28668–76.PubMedCrossRefGoogle Scholar
  77. 77.
    Mantzoros C, Petridou E, Dessypris N et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metabol 2004; 89:1102–7.CrossRefGoogle Scholar
  78. 78.
    Matsuzawa Y. Adipocytokines, insulin resistance and main noncommunicable diseases. In: Berstein LM, ed. Hormones, age and cancer. St Peterburg: Nauka 2005:159–69.Google Scholar
  79. 79.
    Celis JE, Moreira JM, Cabezon T et al. Identification of Extracellular and Intracellular Signaling Components of the Mammary Adipose Tissue and Its Interstitial Fluid in High Risk Breast Cancer Patients: Toward Dissecting The Molecular Circuitry of Epithelial-Adipocyte Stromal Cell Interactions. Mol Cell Proteomics 2005; 4:492–522.PubMedCrossRefGoogle Scholar
  80. 80.
    Iyengar P, Espina V, Williams TW et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest 2005; 115:1163–76.PubMedGoogle Scholar
  81. 81.
    Weisberg SP, McCann D, Desai M et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003; 112:1796–808.PubMedGoogle Scholar
  82. 82.
    Neels JG, Olefsky JM. Inflamed fat: what starts the fire? J Clin Invest 2006; 116:33–5.PubMedCrossRefGoogle Scholar
  83. 83.
    Trayhurn P, Wood IS. Inflammatory cytokines and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92:347–55.PubMedCrossRefGoogle Scholar
  84. 84.
    Furukawa S, Fujita T, Shimabukuro M et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004; 114:1752–61.PubMedGoogle Scholar
  85. 85.
    Lin Y, Berg AH, Iyengar P et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005; 280:4617–26.PubMedCrossRefGoogle Scholar
  86. 86.
    Schaffer A, Muller-Landner U, Scholmerich J et al. Role of adipose tissue as an inflammatory organ in human diseases. Endocr Rev 2006; 27:449–67.CrossRefGoogle Scholar
  87. 87.
    Tripathy D, Mohanty P, Dhindsa S et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003; 52:2882–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Yan B, Wang H, Rabbani ZN et al. Tumor necrosis factor-alpha (TNF-alpha) is a potent endogenous mutagen that promotes cellular transformation. Cancer Res 2006; 66:11565–70.PubMedCrossRefGoogle Scholar
  89. 89.
    Barbier O, Villeneuve L, Bocher V et al. The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene. J Biol Chem 2003; 278:13975–83.PubMedCrossRefGoogle Scholar
  90. 90.
    Baron JA, Greenberg ER. Cigarette smoking and neoplasms of the female reproductive tract and breast. Seminars in Reproductive Endocrinology 1989; 7:335–43.CrossRefGoogle Scholar
  91. 91.
    Kirkwood TBL. Understanding the odd science of aging. Cell 2005; 120:437–47.PubMedCrossRefGoogle Scholar
  92. 92.
    Castagnetta LA, Granata OM, Traina A et al. Tissue content of hydroxyestrogens in relation to survival of breast cancer patients. Clin Cancer Res 2002; 8:3146–55.PubMedGoogle Scholar
  93. 93.
    Blasiak J, Arabski M, Krupa R. DNA damage and repair in type 2 diabetes mellitus. Mutat Res 2004; 554(1–2):297–304.PubMedGoogle Scholar
  94. 94.
    Binkova B, Smerhovsky Z, Strejc P et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death of males. Mutat Res 2002; 501(1–2):115–28.PubMedGoogle Scholar
  95. 95.
    Ozanne SE, Hales CN. Poor fetal growth followed by rapid postnatal catch-up growth leads to premature death. Mech Ageing Dev 2005; 126:852–4.PubMedCrossRefGoogle Scholar
  96. 96.
    Hillestrom PR, Weimann A, Jensen CB et al. Consequences of low birthweight on urinary excretion of DNA markers of oxidative stress in young men. Scand J Clin Lab Invest 2006; 66(5):363–70.PubMedCrossRefGoogle Scholar
  97. 97.
    Alegret M, Silvestre JS. Pleiotropic effects of statins and related experimental approaches. Methods Find Exp Clin Pharmacol 2006; 28(9):627–56.PubMedCrossRefGoogle Scholar
  98. 98.
    Berstein LM. Clinical usage of hypolipidemic and antidiabetic drugs in the prevention and treatment of cancer. Cancer Lett 2005; 224(2):203–12.PubMedCrossRefGoogle Scholar
  99. 99.
    Anisimov VN, Berstein LM, Egormin PA et al. Effect of metformin on life span and on the development of spontaneous mammary tumors in HER-20/neu transgenic mice. Exp Gerontol 2005; 40(8–9):449–66.Google Scholar
  100. 100.
    Klebanov S. Can short-term dietary restriction and fasting have a long-term anticarcinogenic effect? Interdiscip. Top Gerontol 2007; 35:176–92.PubMedGoogle Scholar
  101. 101.
    De Flora S, Ferguson LR. Overview of mechanisms of cancer chemopreventive agents. Mutat Res 2005; 591:8–15.PubMedGoogle Scholar
  102. 102.
    Baur JA, Pearson KJ, Price NL et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444(7117):337–42.PubMedCrossRefGoogle Scholar
  103. 103.
    Yue W, Wang J, Santen RJ et al. Farnesylthyosalicylic acid blocks mammalian target of rapamycin signaling in breast cancer cells. International J Cancer 2005; 117(5):746–54.CrossRefGoogle Scholar
  104. 104.
    Dowling RJ, Zakikhamni M, Fantus IG et al. Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007; 67:10804–12.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2008

Authors and Affiliations

  • Lev M. Berstein
    • 1
  1. 1.Laboratory of OncoendocrinologyProf. N.N. Petrov Research Institute of OncologySt. PetersburgRussia

Personalised recommendations